Index

Figures and Tables are indicated by italic page numbers, Boxes by bold numbers. Abbreviations: ACS = acute coronary syndrome; ECG = electrocardiography; MI = myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST-segment-elevation myocardial infarction; UA = unstable angina

Abciximab 54, 58, 59, 61, 86, 100, 101
Accelerated idioventricular rhythm (AIVR) 87, 164
Access site thrombosis, as complication of angiography/PCI 167
Acidosis, in cardiogenic shock, treatment of 147–8
Acute mitral regurgitation 154–5
Alcohol consumption 203–4
Aldosterone receptor blockers for secondary prevention 182, 184–5 in STEMI 108
trials 185
American College of Cardiology/American Heart Association (ACC/AHA) guidelines on anticoagulant therapy in STEMI 101–2, 156, 190, 191
in UA/NSTEMI 54, 62, 65, 66, 67, 69
on antiplatelet therapy 53–4, 58, 100 conservative compared with early invasive strategies 53
on lipid-lowering therapy 69, 185, 187
on pacemakers 160–1, 162
on percutaneous coronary intervention 89–90, 95
on renin-angiotensin-aldosterone inhibitors 106, 107, 182
on secondary prevention 174, 182–3, 184
on STEMI management 79, 82, 86, 89, 91, 95, 97, 98, 100, 101–2, 103, 105, 106, 107, 156, 190, 191
on UA/NSTEMI management 37, 42, 53–4, 58, 62, 65, 66, 67, 69
Analgesics 43, 46, 109
Anatomy of heart 212
Angiotensin-converting enzyme (ACE) inhibitors
ACC/AHA guidelines 107
for secondary prevention 179–81
in STEMI 105–8
trials 180
in UA/NSTEMI 43, 45–6
Angiotensin receptor blockers (ARBs) for secondary prevention 181, 182
in STEMI 107, 108
trials 183–4
Anterior wall MI bradycardia and AV block 159
ECG 22–3, 161, 209, 210
localizing site of occlusion 22
MRI image 32
in pregnant women 135
timing of hospital discharge 113–14
Antiarrhythmic agents 109–10
Antiarrhythmic devices 195–8
Anticoagulant therapy 9–10
combination with antiplatelet therapy 191–2, 193
in LV intracavitary thrombosis 156
for secondary prevention 189–90, 191–2
in STEMI 101–5, 156
ACC/AHA guidelines 101–2, 156
concurrent with fibrinolysis 85–6, 102
in UA/NSTEMI 39, 61–8
ACC/AHA guidelines 54, 62, 65, 66, 67, 69
Antioxidant vitamins 192
Antiplatelet therapy 9
for secondary prevention 173–7
in STEMI 98–101
ACC/AHA guidelines 100
in UA/NSTEMI 39, 49, 54–61
ACC/AHA guidelines 53–4, 58
Antithrombin 8, 9
Anxiolytics 109
Aortic dissection
contraindication for fibrinolysis 84
as differential diagnosis of chest pain 15
Apical ballooning syndrome 133–4
Argatroban 10, 65
Arrhythmic complications of ACS 159–64
Aspirin 8, 9
ACC/AHA guidelines 53, 174
combinations with clopidogrel 55, 56, 99, 177
warfarin 67–8, 104–5, 191–2
contraindications 55
desensitization protocol(s) 55, 98, 211
pericarditis treated with 158
for secondary prevention 173–4
in STEMI 81, 98
in UA/NSTEMI 53, 54–5, 54
Diabetes mellitus, ACS and 123–7
Diabetics coronary revascularization 126–7
glycemic control in patients with ACS 125–6, 198–9
primary ACS therapy 124–5
Diagnosis (of ACS) 13–35
cardiac biomarkers 26–9
differential diagnosis 15–16, 133, 134
ECG 19–26
noninvasive imaging 29–32
overall diagnostic pathway 32–4
physical examination 17–19
stress testing 32
Dialysis patients, ACS medications 61, 129
Dietary recommendations 202–3
Diltiazem 43, 45, 109
Direct thrombin inhibitors 8, 10, 65–6
see also argatroban; bivalirudin; hirudin; lepirudin
Dressler’s syndrome 158
Dynamic obstruction, development of ACS affected by 10

Echocardiography 29–30, 70
in right ventricular myocardial infarction 149
standard views 213
Electrical storm 163
Electrocardiography (ECG) 19–26
pathophysiologic basis of ST segment changes 19–20
in right ventricular myocardial infarction 23, 26, 149, 150
in UA/NSTEMI 26
Emergency department measures 32–3, 42, 82–3, 101
Enalapril 43, 180
Enoxaparin advantages over unfractionated heparin 63
contraindications 65
dosage 65, 103
in STEMI 86, 101, 102–3, 102
trials 63–4
in UA/NSTEMI 62–5
see also low molecular weight heparin (LMWH)
Eplerenone 108, 184, 185
Eptifibatide 54, 58, 59–60, 61, 100
contraindication 129
Estrogen replacement therapy 192, 194
Exercise-based therapy 192, 194
Exercise-tolerance testing 32, 69, 70
Extracorporeal membrane oxygenation (ECMO) system 145, 147
Ezetimide 187

Factor Xa inhibitor 10, 66, 104
see also fondaparinux
Fenofibrate 69
Fibrates, in lipid-lowering therapy 69, 185, 187–9, 188
Fibrinogen 8
Fibrinolysis complications 68, 88
contraindications 68, 83, 84
for STEMI 81–2, 83–8
combined with GPIIb/IIIa inhibitors 86
concurrent anticoagulant therapy 85–6
effectiveness markers 86–8
fibrinolytic agents 85
for UA/NSTEMI 68
compared with PCI 90–3
see also thrombolytic therapy
Fish oil 189, 204
Fondaparinux 8, 10, 54, 66–7, 101, 102, 104
Gemfibrozil 69, 187, 188
General appearance of patient 17–19
Glomerular filtration rate (GFR), estimation of 129
Glycoprotein (GP) IIb/IIIa inhibitors 8, 9
side effects 61
in STEMI 100–1
in UA/NSTEMI 53, 54, 58–61
trials 59–60
see also abciximab; eptifibatide; tirofiban
Glycoprotein (GP) IIb/IIIa receptor 8

Hematoma, as complication of angiography/PCI 166
Hemodynamic calculations 216
Hemodynamic waveforms 216
in RVMI 149, 151
Hemostasis primary 7–8
pharmacologic agents affecting 9
secondary 9
pharmacologic agents affecting 9–10
Heparin LMWH compared with UFH 63–4
low molecular weight (LMWH) 8, 9, 54, 62–5, 86, 102–3
unfractionated (UFH) 8, 9, 54, 61–2, 85–6, 101, 102, 102, 156
Heparin-induced thrombocytopenia thrombosis (HITT) syndrome, anticoagulant used 66
Hirudin 65
History 14–16
Hormone replacement therapy (HRT) 192, 194
Hyperglycemia, treatment of 110, 198–9
Hypertension, control in secondary prevention 199
Hypothyroidism, ACS and 136–7
Hypoxemia, in cardiogenic shock, treatment of 145, 147

Implantable cardioverter defibrillator (ICD) therapy 195
timing of ICD implantation 198
trials 196–7
Inferior wall MI 159
bradycardia and AV block 23, 162, 210–17
localizing site of occlusion 24
Inflammation development of ACS affected by 11
marker 6
Index

Influenza vaccination 192
Inotropic agents, in management of cardiogenic shock 145, 146
Intraaortic balloon pump (IABP) 43, 44, 145, 147, 215
Intracranial hemorrhage (ICH) causes 55, 68, 83, 88, 164
emergency treatment of 88, 164–5
fatality rate 164
risk score 164, 165
Invasive strategy 46, 47
compared with conservative strategy 46–9
ACC/AHA recommendations 53
trials 50–2
see also coronary angiography; percutaneous coronary intervention
Ischemic papillary muscle dysfunction 154
Killip classification 142, 143
Kussmaul’s sign 149
Left ventricular aneurysm 105, 155–7
Left ventricular ejection fraction (LVEF) 112–13
Left ventricular free wall rupture 152–3
Left ventricular intracavitary thrombosis 156
Left ventricular mural thrombus, treatment of 190
Left ventricular myocardial infarction, symptoms 148
Left ventricular pseudoaneurysm 153, 157
Lepirudin 65
Levine sign 18
Lifestyle recommendations 200–4
Lipid-lowering therapy for secondary prevention 185–9
in UA/NSTEMI 68–9
Lisinopril 43, 46
Losartan 182, 183, 184
Low molecular weight heparin (LMWH) 8, 9, 54, 62–5
compared with unfractionated heparin 63–4
in STEMI 86, 102–3
in UA/NSTEMI 54, 62–5
see also enoxaparin
Magnetic resonance imaging 31, 32
Mechanical complications of ACS 152–5
algorithm for diagnosis and therapy 155
left ventricular free wall rupture 152–3
Metabolic syndrome
ACS and 127, 202
criteria defining 127
Metoprolol 43, 44, 105, 129
Mitral regurgitation 154–5
Morphine sulfate 43, 46, 109
Myocardial infarction
definition(s) 13–14, 28
prehospital management and triage 80–2
transport decisions 82
see also non-ST-segment-elevation myocardial infarction (NSTEMI); ST-segment-elevation myocardial infarction (STEMI)
Myocardial ischemia 1, 7, 38
pharmacologic treatment of 39, 43–6
Myocardial oxygen balance factors affecting 6
results of imbalance 6, 7, 38
Myocardial perfusion imaging 30, 70
Myocarditis 16, 132–3
Neck examination 18–19
Nephropathy contrast-induced 128
see also chronic kidney disease (CKD)
New-onset angina 38–9
Niacin, in lipid-lowering therapy 69, 185, 188
Nifedipine, avoidance of use 45, 109
Nitrate therapy 44–5, 108–9
RVMI and 151
Nitroglycerin in STEMI 108–9
in UA/STEMI 43, 44–5
Noninvasive imaging 29–32
cardiovascular magnetic resonance imaging 31, 32
coronary computed tomography 30, 31
echocardiography 29–30
myocardial perfusion imaging 30
Noninvasive risk stratification, predischarge 69–70, 71, 112–13
Nonsteroidal anti-inflammatory agents (NSAIDs) 158, 194, 195
Non-ST-segment-elevation acute coronary syndromes (NSTEACS), see unstable angina and non-ST-segment-elevation myocardial infarction (UA/NSTEMI)
Non-ST-segment-elevation myocardial infarction (NSTEMI) 37
Nonsustained ventricular tachycardia 163–4
Normal coronary arteries, ACS in patients with 132
Omega-3 fatty acids 189, 204
Oral anticoagulants 67–8
Oxygen therapy 46, 111
Pacemakers
ACC/AHA guidelines 160–1, 162
permanent 161–2
temporary transvenous 160
Papillary muscle rupture 154–5
Pathophysiology (of ACS) 1–11
Percutaneous coronary intervention (PCI) 88–97
complications arising 165–70
following fibrinolytic therapy 94–7
ACC/AHA guidelines 95
delayed routine PCI 96–7
facilitated PCI 94–6
rescue PCI 88, 94
compared with coronary artery bypass surgery 126–7
compared with fibrinolysis 90–3
see also primary PCI

Perfusion imaging 30, 70
Pericardial complications 157–8
Pericardial effusion 158
Pericarditis 16, 76, 133
   early postinfarction 157–8
   late postinfarction 158
Perindopril 180
Peripartum MI 135
Peripheral vasculature, examination 18
Physical examination 17–19
   non-ACS diagnosis 17, 18
Plaque
   stabilization of 39
   see also atherosclerotic plaque
Platelet activation 8
Platelet adhesion 7, 8
Platelet aggregation 8
Posterior wall MI
   bradycardia and AV block 159
   ECG 23, 83
Post-hospitalization care 173–208
   lifestyle recommendations 200–4
   limited-benefit medications 192–5
   nonpharmacologic measures 195–8
   pharmacologic measures 173–92
   therapy of comorbidities 198–200
Postoperative ACS 134
Prasugrel 9, 57–8, 99–100
Pravastatin 68, 186
Prehospitalization care 173–208
   ACC/AHA recommendations 89–90
   GP IIb/IIIa inhibitors used in laboratory 100–1
   pretreatment with cilostegrel 56–7, 99
   pretreatment with GP IIb/IIIa inhibitors 101
   timing aspects 91–3
   see also percutaneous coronary intervention
Pseudoaneurysm
   as complication of angiography/PCI 166
   left ventricular 153, 157
Pulmonary artery catheter, in management of cardiogenic shock 144
Pulmonary embolism, as differential diagnosis of chest pain 15
Pulmonary examination 19
Pump failure, cardiogenic shock due to 141–8
Radiation burn, as complication of angiography/PCI 169
Radiation therapy, ACS caused by 137
Ramipril 46, 180, 181
Renal failure, as complication of angiography/PCI 168–9
Renal function
   ACS and 128
   adjustment of ACS medications 129
Renin–angiotensin–aldosterone inhibitors 105–8, 179–85
   see also aldosterone receptor blockers; angiotensin-converting enzyme (ACE) inhibitors; angiotensin receptor blockers
Reperfusion therapy for STEMI patients 83–97
   factors affecting choice of strategy 93
   fibrinolysis 83–8
   hospital care following 110–11
   overall strategy 97
   primary percutaneous coronary intervention 88–97
Rest angina 38
Retegase (rPA) 85
Retroperitoneal bleeding, as complication of angiography/PCI 167
Right heart catheterization 149, 216
Right ventricular myocardial infarction (RVMI) 148–52
   causes 148
   clinical presentation 148–9
   diagnosis 149, 150
   ECG 23, 26, 149, 150
   effect of nitrates 108–9, 151
   management 150–2
   prognosis 152
   Risk factors 17, 173, 174
   Risk stratification
   after STEMI 112–13, 156
   in UA/NSTEMI 40–2, 69–70, 71
Rofexocib 194–5
Secondary unstable angina 38, 123
   causes 124
   development of ACS affected by 11
   Sertraline 200
   Severe LV dysfunction, anticoagulation therapy 190–1
   Sexual activity after ACS 201
   Simvastatin 186, 187
   Sinus bradycardia 159
   Smoking cessation 201, 202
   Spironolactone 184, 185
Statins
   in combination therapy 69, 188
   for secondary prevention 185–7, 188
   in UA/NSTEMI management 68–9
Stent thrombosis 17
Streptokinase (SK) fibrinolysis 85, 104
Stress testing
   diagnosis of ACS 32
   prior to discharge 69–70, 113
   safety assessment prior to 113
Stroke
   as complication of angiography/PCI 168
   contraindication for fibrinolysis 84
   ST-segment-elevation, causes 21, 133
ST-segment-elevation myocardial infarction (STEMI) 79–121
adjunctive pharmacologic treatment 98–100
anticoagulation therapy 101–5
antiplatelet agents 98–101
coronary artery bypass grafting 98
discharge noninvasive risk stratification 112–13
ECG 20–6
educational strategy 111–12
emergency department measures 82–3
global treatment goals 80–1
prehospital management and triage 80–2
reperfusion therapy
checklist 84
fibrinolysis 83–8
PCI following fibrinolysis 94–7
primary percutaneous coronary intervention 88–93
timing of hospital discharge 113–14
transport decisions 82
Subendocardial ischemia 20
ECG 26
Symptoms, ACS 14–16

Takotsubo cardiomyopathy 133
Tenecteplase (TNK) 85
Tension pneumothorax, as differential diagnosis of chest pain 16
Thienopyridines 9, 55–8, 99–100
see also clopidogrel; prasugrel; ticlopidine
Thrombin 8
production of 9
role in thrombosis 9
Thrombolytic therapy 68, 81–2, 83–8
contraindications 68, 83, 84
see also fibrinolysis
Thrombus formation 1, 7, 8
pharmacologic agents affecting 8, 9–10
Ticlopidine 9, 56
side effect(s) 56
TIMI flow grade(s), as artery-patency marker 86, 87
TIMI Risk Score
for STEMI 80, 81
for UA/NSTEMI 41–2
Tirofiban 54, 58, 60, 61, 100
Tissue plasminogen activator (tPA) 85
Trandolapril 180
Transient apical ballooning syndrome 133–4
Transmural ischemia 20
Transmural necrosis 152, 153
Transport decisions 82

Trauma
ACS and 137
contraindication for fibrinolysis 84
Treadmill exercise testing 69, 70
Triage 42, 80–2
Troponin 26, 27, 28

Unfractionated heparin (UFH) 8, 9
in STEMI 85–6, 101, 102, 102, 156
in UA/NSTEMI 54, 61–2
compared with low molecular weight heparin 63–4
Unstable angina and non-ST-segment-elevation myocardial infarction (UA/NSTEMI) 37–78
anticoagulant therapy 39, 61–8
antiplatelet therapy 39, 49–61
causes 37–8
ECG 26
emergency treatment 42
fibrinolysis 68
general strategies for management 39–40
lipid-lowering therapy 68–9
overall management pathway 71
pharmacologic treatment of coronary ischemia 39, 43–6
post-discharge care strategies 40–1
predischarge risk stratification 69–70, 71
presentation 38–9
risk stratification of patients 40–2
TIMI Risk Score 41–2
Urokinase 85

Valsartan 107, 182, 183
Ventricular assist devices 145, 147
Ventricular fibrillation 163
Ventricular premature beats 163–4
Ventricular septal rupture (VSR) 153–4
Ventricular tachyarrhythmias 156, 163–4
treatment of 110, 163
Verapamil 43, 45, 109
Vital signs 18
Vitamins 192

Waist circumference 203
Warfarin 67–8, 104–5, 156, 189–92
combination with aspirin 67–8, 104, 191–2
Weight loss recommendations 203
Worsening angina 39

Young patients with ACS 130